Ensoma is a Boston-based biotechnology company focused on engineering hematopoietic stem cells directly inside the body to create durable genetic medicines for genetic diseases, immune disorders, and cancer. Its platform uses high-capacity virus-like particles (VLPs) that selectively target HSCs and can deliver up to 35 kb of genetic cargo, enabling single-base edits through large multi-gene insertions. The company combines these VLPs with proprietary base-editing and gene-integration systems, aiming for one-time intravenous administration. Proceeds from its latest financing will fund a Phase 1/2 clinical trial of lead candidate EN-374 for X-linked chronic granulomatous disease and support platform expansion into immuno-oncology and sickle cell programs. Ensoma’s strategy centers on creating off-the-shelf, non-myeloablative treatments that avoid the complexity and cost of ex vivo cell processing. The firm’s board now includes a Gilead appointee following the strategic investment. No financial metrics or commercial revenues have been disclosed to date.

Total raised

$258M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2025